Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseases

Coultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe.

The capital will be used to develop a new approach that targets salt‑inducible kinase (SIK) inhibition, aiming to create a pipeline‑in‑a‑pill solution for autoimmune conditions.

The raise positions Coultreon to expand its research program and move its candidate toward clinical testing, reflecting growing investor interest in novel immunology targets.

Industry observers see the funding as a positive signal for the company’s strategy and for the broader field of autoimmune drug development.